Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03207646 · ClinicalTrials.gov registry record · NA
Smartphone GUIded MeDication AdherencE and Rehabilitation in Patients With Coronary Artery Disease
A NA study, sponsored by Stanford University.
- Terminated
- Registry status
- NA
- Development phase
- 63
- Enrollment target
NCT03207646: Clinical Trial NA study, sponsored by Stanford University.
NCT03207646 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 63 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03207646, a NA study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
Study Summary
This study evaluates a smartphone-based cardiac rehabilitation program in adults with coronary artery disease. Half of patients will participate in a smartphone-based cardiac rehabilitation program while the other half will receive standard-of-care.
Primary Outcome
The proportion of days coverd (PDC) expressed as a percentage but considered as a continuous variable of the composite of the prescribed P2Y12 receptor antagonist and/or the statin.
Interventions
- OTHER BrightHeart®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2018-08-17 |
| Phase | NA |
Why NCT03207646 stopped before completion
NCT03207646 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which BrightHeart® is the first listed.
NCT03207646 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03207646 about?
NCT03207646 is a clinical study titled "Smartphone GUIded MeDication AdherencE and Rehabilitation in Patients With Coronary Artery Disease". This study evaluates a smartphone-based cardiac rehabilitation program in adults with coronary artery disease. Half of patients will participate in a smartphone-based cardiac rehabilitation program while the other half will receive standard-of-care.
What is the current status of trial NCT03207646?
This trial is currently terminated. It is a NA study. The enrollment target is 63 participants. The study started on 2017-07-19. Estimated completion is 2018-08-17.
What interventions are being tested in trial NCT03207646?
The interventions under investigation include: BrightHeart® (OTHER).
Who is sponsoring clinical trial NCT03207646?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03207646's enrollment target sits among peer trials
63 1157th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI